Skip to main content Skip to search Skip to main navigation

FDA: Launch of “Elsa” AI Tool

The U.S. Food and Drug Administration (FDA) has launched Elsa, a generative AI tool aimed at enhancing the productivity of its employees, from scientists to investigators.

Key Highlights:

  • Accelerated Rollout:
    • Launched ahead of the June 30 target
    • Delivered under budget, thanks to cross-agency collaboration
  • Secure & Private:
    • Built within a high-security GovCloud
    • Does not train on data from regulated industries
    • Keeps all information internal to the FDA
  • Early Impact:
    • Speeds up clinical protocol reviews and scientific evaluations
    • Helps identify top inspection priorities
  • Functional Capabilities:
    • Summarizes adverse events for safety reviews
    • Performs label comparisons
    • Generates code for nonclinical database development
  • Future Plans:
    • Elsa is the first step in a broader AI strategy
    • More AI tools to be integrated into FDA operations over time, such as data processing and generative-AI functions

Source:

FDA: Press Announcements


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: Q&A on QP Certification Without Physical EU Import

EMA: Q&A on QP Certification Without Physical EU Import

The EMA has published a new Q&A addressing QP certification for batches that are neither manufactured within the EU/EEA nor intended for the EU/EEA market, and that are not physically imported into the EU/EEA.

Read more
EU: Agreement on the Pharmaceutical Package

EU: Agreement on the Pharmaceutical Package

On 11 December, the European Commission, the European Parliament, and the Council of the European Union reached a provisional agreement to update Europe's medicinal products regulatory framework.

Read more
EMA: Updated Q&As for Biological Medicinal Products

EMA: Updated Q&As for Biological Medicinal Products

EMA has updated its Q&A on biological medicinal products, addressing topics that previously required clarification or were subject to differing interpretation. The latest revision adds six new questions and updates several existing answers.

Read more
ICH: New Recommendations for the Manufacture of ATMPs

ICH: New Recommendations for the Manufacture of ATMPs

The ICH’s Cell and Gene Therapy Discussion Group (CGTDG), which was established in May 2023, has provided recommendations with regard to future Advanced Therapy Medicinal Products (ATMPs) Related Guidelines.

Read more
GMP Publishing Embarks on a new Digital Chapter

GMP Publishing Embarks on a new Digital Chapter

After months of intensive work, creative ideas, and technical finesse, the time has finally come: the GMP Verlag website has been given a fresh new look.
Read more
 Basics on the Integrity of Container Closure Systems

Basics on the Integrity of Container Closure Systems

The integrity of a primary packaging system (container closure system) is essential to prevent product loss by leakage or evaporation and at the same time protect the product from contamination. The task of a primary packaging system (container closure system) is essentially to prevent the product from being lost (e.g. leakage, evaporation, etc.) and to prevent the product from being contaminated from the outside.

Read more
Previous
Next